Accessibility Menu
 
Intensity Therapeutics logo

Intensity Therapeutics

(NASDAQ) INTS

Current Price$5.61
Market Cap$14.48M
Since IPO (2023)-96%
5 YearN/A
1 Year-89%
1 Month-24%

Intensity Therapeutics Financials at a Glance

Market Cap

$14.48M

Revenue (TTM)

$0.00

Net Income (TTM)

$11.61M

EPS (TTM)

$-11.64

P/E Ratio

-0.49

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$5.61

Volume

23,904

Open

$5.83

Previous Close

$5.70

Daily Range

$5.65 - $5.83

52-Week Range

$4.63 - $50.00

INTS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Intensity Therapeutics

Industry

Biotechnology

Employees

16

CEO

Lewis H. Bender, MBA

Headquarters

Westport, CT 06880, US

INTS Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-157%

Return on Capital

-1%

Return on Assets

-82%

Earnings Yield

-2.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.48M

Shares Outstanding

2.54M

Volume

23.90K

Short Interest

0.00%

Avg. Volume

52.16K

Financials (TTM)

Gross Profit

$26.00K

Operating Income

$11.97M

EBITDA

$11.97M

Operating Cash Flow

$9.23M

Capital Expenditure

$0.00

Free Cash Flow

$9.23M

Cash & ST Invst.

$11.92M

Total Debt

$110.00K

Intensity Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$7.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$14.48M

N/A

Market Cap/Employee

$2.90M

N/A

Employees

5

N/A

Net Income

$3.05M

+4.1%

EBITDA

$3.13M

+1.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$11.81M

+381.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$79.00K

-28.2%

Short Term Debt

$31.00K

+10.7%

Return on Assets

-82.31%

N/A

Return on Invested Capital

-1.00%

N/A

Free Cash Flow

$2.40M

+10.0%

Operating Cash Flow

$2.40M

+10.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PSTVPlus Therapeutics, Inc.
$3.56-8.60%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
BOLDBoundless Bio, Inc.
$1.08-4.42%
PLURPluri Inc.
$3.32-0.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.31-0.02%

Questions About INTS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.